High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. [electronic resource]
Producer: 20010531Description: 2370-80 p. digitalISSN:- 0732-183X
- Adult
- Aged
- Cancer Vaccines -- immunology
- Disease-Free Survival
- Female
- G(M2) Ganglioside -- immunology
- Hemocyanins -- immunology
- Humans
- Immunoglobulin G -- blood
- Immunoglobulin M -- blood
- Interferon alpha-2
- Interferon-alpha -- adverse effects
- Male
- Melanoma -- drug therapy
- Middle Aged
- Neoplasm Staging
- Prospective Studies
- Recombinant Proteins
- Saponins
- Vaccination
- Vaccines, Conjugate -- immunology
No physical items for this record
Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.